Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

Pinealon

Pinealon is a synthetic Glu-Asp-Arg tripeptide. This profile reviews one oxidative-stress cell study and one rat prenatal hyperhomocysteinemia study from one group, and two small uncontrolled or non-randomised human reports (abstracts only); other Russian-language reports were not reviewed. No approved use was found.

Aliases reviewed
Glu-Asp-Arg, EDR
Sources checked
2026-10-28
Editorial status
published

Evidence at a glance

Human
LimitedTwo small uncontrolled or non-randomised human reports reviewed, abstracts only
Animal/cell
LimitedOne cell study (abstract) and one rat study (full text), one group; others not reviewed
Approved medicine
None foundScope: Canadian DPD searches and the sources reviewed; no approved product found.

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. This concise profile was researched from primary and regulatory records; supplier listings were used only to find the name.

Identity

Pinealon is described in its primary research papers as the synthetic tripeptide Glu-Asp-Arg; PubChem resolves the name to Glu-Asp-Arg (CID 10273502, molecular formula C15H26N6O8) and lists the one-letter sequence E-D-R (written EDR here) among its synonyms. It is a separate molecule from the catalogue's Epithalon profile, and findings for one cannot be assigned to the other. A chemical identity record does not establish the identity, salt form or purity of any catalogue material sold under the name.

Biological mechanism or research interest

In cerebellar granule cells, neutrophils and PC12 cells exposed to oxidative stress, a 2011 laboratory study reported lower reactive-oxygen-species accumulation, less necrotic cell death, delayed ERK 1/2 activation and cell-cycle changes. The authors' suggestion that the peptide may act directly on the cell genome is a hypothesis, not a demonstrated mechanism. Research interest centres on oxidative stress and neuronal cell survival in laboratory and rodent models.

Verified approved human uses

Health Canada's Drug Product Database active-ingredient search returned no records for "pinealon" or for "Glu-Asp-Arg" on the access date. That establishes only the absence of a Canadian product record under those names; it is not a worldwide review, and other jurisdictions were not searched here. No approved human use was verified in the sources reviewed.

Investigational human evidence

Two small Russian human reports involving pinealon were reviewed here, read as PubMed abstracts only; other short Russian-language human reports involving pinealon, including occupational and geroprotection reports, are indexed in PubMed but were not reviewed. A 2015 report studied the synthetic peptides pinealon and vesugen in 32 adults aged 41-83 with chronic polymorbidity and organic brain syndrome in remission; no control group, placebo or blinding was described, and outcomes were biological-age and laboratory markers. A 2012 report on psychoadaptive disorders compared 150 male truck drivers with 150 male metal craftsmen and reported effects of peptide use, best with pinealon combined with vesugen; the abstract does not describe how many people received the peptides, randomisation, placebo or blinding, so effects cannot be assigned to pinealon alone. Neither establishes a clinical benefit, safety profile or approved use.

Brain-health, cognitive and anti-aging claims extend beyond the findings reviewed. The cell and rat findings concern oxidative-stress markers, necrotic cell counts and early maze performance in laboratory models, not human outcomes. The two human abstracts report biomarker and questionnaire findings from small reports without described randomisation, placebo or blinding, and both also involved vesugen, so they do not demonstrate a neuroprotective, cognitive or anti-aging effect of pinealon in people.

Human versus animal or cell evidence

The 2011 findings come from cultured cells only. A 2012 rat study gave pinealon by intraperitoneal injection to pregnant rats with methionine-induced hyperhomocysteinemia and reported better early water-maze performance and, in offspring cerebellar granule cells, fewer necrotic cells and less reactive-oxygen-species accumulation after a laboratory hydrogen-peroxide challenge (baseline ROS did not differ), without lowering blood homocysteine; group differences in the maze had disappeared by the fifth trial. Other short Russian-language animal and cell reports on pinealon are indexed in PubMed but were not reviewed here.

Limitations and known risks

Human pharmacokinetics, safety, dose-response and interactions are not characterised in the sources reviewed. The 2015 human abstract also reported pro-oxidant activity on chemiluminescence and lower blood CD34+ cell markers for the peptides studied, which the authors described as inhibition of haemopoiesis, and its sex breakdown (18 men, 12 women) does not add up to the 32 participants stated. The reviewed preclinical papers come from one research group, and the rat study used small biochemical samples without described blinding. The catalogue material's identity and quality are unverified.

What this profile is—and is not

Concise source review from primary and regulatory records, independently checked for source accuracy; supplier listings were used only to find the name. Recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.